TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34160587

Group type: EXPERIMENTAL
Intervention: Development cohort (n=4172)
Number of subjects: 8403

Group type: EXPERIMENTAL
Intervention: Validation cohort (n=4231)
Number of subjects: 8403
Study: 32363972

Group type: EXPERIMENTAL
Intervention: Pre-infusion single-dose mesenchymal stem cells (1 × 10^6 cells/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group without MSCs
Number of subjects: 50
Study: 33300754

Group type: EXPERIMENTAL
Intervention: Rule of thirds for detecting excessive anterior acetabular wall coverage
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rule of thirds for detecting excessive posterior acetabular wall coverage
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rule of thirds for detecting deficient anterior acetabular wall coverage
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rule of thirds for detecting deficient posterior acetabular wall coverage
Number of subjects: 161
Study: 34225296

Group type: EXPERIMENTAL
Intervention: Postinjury firearm weapon carriage
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: PTSD symptom levels
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Firearm weapon carriage at 3- and 6-months postinjury
Number of subjects: 128
Study: 32370778

Group type: EXPERIMENTAL
Intervention: Lurasidone continuation
Number of subjects: 223

Group type: COMPARATOR
Intervention: Risperidone switch to Lurasidone
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Lurasidone continuation (males)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Risperidone switch to Lurasidone (males)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Lurasidone continuation (females)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Risperidone switch to Lurasidone (females)
Number of subjects: 223
Study: 35728875

Group type: EXPERIMENTAL
Intervention: Spartalizumab 400 mg intravenously every 4 weeks plus dabrafenib 150 mg orally two times daily and trametinib 2 mg orally one time daily
Number of subjects: 532

Group type: COMPARATOR
Intervention: Placebo plus dabrafenib and trametinib
Number of subjects: 532
Study: 33759278

Group type: EXPERIMENTAL
Intervention: Experimental group (digital image altered to match patient's desired hand appearance)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (unaltered image)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Experimental group (follow-up after repeated interventions)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (follow-up after repeated interventions)
Number of subjects: 45
Study: 32675595

Group type: EXPERIMENTAL
Intervention: Heated intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intraperitoneal chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIPEC
Number of subjects: 0
Study: 32224742

Group type: EXPERIMENTAL
Intervention: Anastomotic leakage in rectal cancer patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anastomotic leakage in colon cancer patients
Number of subjects: 0
Study: 34441967

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical corticosteroid (triamcinolone 0.05%)
Number of subjects: 30
Study: 32678062

Group type: EXPERIMENTAL
Intervention: Mailing of FIT kits
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Mailing of FIT kits plus CHR outreach
Number of subjects: 165

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 165
Study: 36250667

Group type: EXPERIMENTAL
Intervention: Voucher use in low copay group
Number of subjects: 7351

Group type: EXPERIMENTAL
Intervention: Voucher use in middle copay group
Number of subjects: 7351

Group type: EXPERIMENTAL
Intervention: Voucher use in high copay group
Number of subjects: 7351

Group type: COMPARATOR
Intervention: High copay group without voucher
Number of subjects: 7351
Study: 33331846

Group type: EXPERIMENTAL
Intervention: Taxane chemotherapy with indoximod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Taxane chemotherapy without indoximod (control)
Number of subjects: 0
Study: 35138648

Group type: EXPERIMENTAL
Intervention: 6-month dental home visits and education leaflets
Number of subjects: 176

Group type: COMPARATOR
Intervention: education leaflets alone
Number of subjects: 176
Study: 34554106

Group type: EXPERIMENTAL
Intervention: BUP/NX-F with Incentivized Abstinence and Adherence Monitoring (experimental, n=70)
Number of subjects: 141

Group type: COMPARATOR
Intervention: BUP/NX-F in usual care (control, n=71)
Number of subjects: 141
Study: 36418750

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity walking on a treadmill up to volitional exhaustion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking with individually selected speed for 20 min
Number of subjects: 10
Study: 34181478

Group type: EXPERIMENTAL
Intervention: 372 mg ISAVUSULF intravenous solution via nasogastric tube
Number of subjects: 0

Group type: COMPARATOR
Intervention: 372 mg ISAVUSULF capsules for oral administration
Number of subjects: 0
Study: 32679239

Group type: EXPERIMENTAL
Intervention: Mean Spo2
Number of subjects: 2687

Group type: EXPERIMENTAL
Intervention: Baseline Spo2
Number of subjects: 2687

Group type: EXPERIMENTAL
Intervention: Desaturation duration and desaturation/resaturation time ratio
Number of subjects: 2687
Study: 35940738

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study: 32919046

Group type: EXPERIMENTAL
Intervention: Internal rotation at 30° in scapular plane elevation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Horizontal adduction at 60° of elevation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Internal rotation at 30° of flexion
Number of subjects: 9
Study: 32712103

Group type: EXPERIMENTAL
Intervention: Standard of care lifestyle advice
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 32892184

Group type: EXPERIMENTAL
Intervention: Coordination Training (CT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Resting session (control condition)
Number of subjects: 35
Study: 35711602

Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine (DEX)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intranasal Normal Saline (NS)
Number of subjects: 72
Study: 33562180

Group type: EXPERIMENTAL
Intervention: Simultaneous use of human and dog activity trackers for eight weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Use of human activity trackers only
Number of subjects: 80

Group type: COMPARATOR
Intervention: Use of dog activity trackers only
Number of subjects: 80

Group type: COMPARATOR
Intervention: No activity trackers used
Number of subjects: 80
Study: 35726861

Group type: EXPERIMENTAL
Intervention: Pecha kucha training via smartphone
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (standard discharge education)
Number of subjects: 140
Study: 32336643

Group type: EXPERIMENTAL
Intervention: Plasma lactate levels
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intestinal fatty acid binding protein in plasma (I‐FABPp)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intestinal fatty acid binding protein in urine (I‐FABPu)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: I‐FABPp for predicting surgical NEC
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: I‐FABPu for predicting surgical NEC
Number of subjects: 55
Study: 35657028

Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 0
Study: 34463032

Group type: EXPERIMENTAL
Intervention: Bempedoic acid (240 mg/day, supratherapeutic dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 0
Study: 32042073

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (IHG) at 40% maximal handgrip force for 3 minutes
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (IHG)
Number of subjects: 333
Study: 32398091

Group type: EXPERIMENTAL
Intervention: Cruciferous vegetables (4 servings, 300 g per day as a soup, 500-600 mL/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control soup (other commonly consumed vegetables: potato, sweet potato, carrot, pumpkin)
Number of subjects: 25
Study: 36271264

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 0
Study: 32295778

Group type: EXPERIMENTAL
Intervention: In vitro maturation (IVM)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard in vitro fertilisation (IVF)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: IVM
Number of subjects: 350

Group type: COMPARATOR
Intervention: IVF
Number of subjects: 350
Study: 33568343

Group type: EXPERIMENTAL
Intervention: Low-dose fractionated radiation (LDFRT) with PD-L1/CTLA-4 inhibition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation (HFRT) with PD-L1/CTLA-4 inhibition
Number of subjects: 18

Group type: COMPARATOR
Intervention: PD-L1/CTLA-4 inhibition
Number of subjects: 18
Study: 32623230

Group type: EXPERIMENTAL
Intervention: Monthly income supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bimonthly income supplement
Number of subjects: 0
Study: 33152520

Group type: EXPERIMENTAL
Intervention: BTI+self‐rehabilitation (R group)
Number of subjects: 33

Group type: COMPARATOR
Intervention: BTI alone (C group)
Number of subjects: 33
Study: 32841158

Group type: EXPERIMENTAL
Intervention: Sexuality education program (four weekly 2-hour sessions)
Number of subjects: 102
Study: 34311553

Group type: EXPERIMENTAL
Intervention: Authority role (neighbor, teacher, family, clergy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Victim gender (male, female)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactions between authority role and victim gender
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Authority positions (teachers)
Number of subjects: 0
Study: 33798214

Group type: EXPERIMENTAL
Intervention: Emotion storyboards
Number of subjects: 407

Group type: COMPARATOR
Intervention: Vignettes
Number of subjects: 407
Study: 32883211

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided tracheal intubation (Group UG, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Shikani optical stylet-aided tracheal intubation (Group SOS, n = 30)
Number of subjects: 60
Study: 35335885

Group type: EXPERIMENTAL
Intervention: T-ChOS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 32485917

Group type: EXPERIMENTAL
Intervention: Retromalleolar technique
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Supramalleolar technique
Number of subjects: 110
Study: 35077638

Group type: EXPERIMENTAL
Intervention: Muscle Energy (ME) treatment
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High-Velocity Low-Amplitude (HVLA) treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparison of post-first-treatment values to pre-second-treatment values
Number of subjects: 34
Study: 34045002

Group type: EXPERIMENTAL
Intervention: COVID-19 containment measures
Number of subjects: 62837
Study: 36062735

Group type: EXPERIMENTAL
Intervention: Moving to Opportunity treatment (housing vouchers)
Number of subjects: 2829

Group type: COMPARATOR
Intervention: Control group (remained in public housing)
Number of subjects: 2829
Study: 33714677

Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36283162

Group type: EXPERIMENTAL
Intervention: Upper airway radiofrequency (RF) tissue reduction under local anesthesia (LA)
Number of subjects: 30
Study: 32700212

Group type: EXPERIMENTAL
Intervention: Right-sided percutaneous transhepatic biliary drainage (RPTBD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Left-sided percutaneous transhepatic biliary drainage (LPTBD)
Number of subjects: 50
Study: 32283078

Group type: EXPERIMENTAL
Intervention: Pedicled buccal fat pad (group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Abdominal fat (group B)
Number of subjects: 36
Study: 35979900

Group type: EXPERIMENTAL
Intervention: Generic fidaxomicin (test formulation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Original brand fidaxomicin (reference formulation)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 18
Study: 33947913

Group type: EXPERIMENTAL
Intervention: IAsp biosimilar RD10046
Number of subjects: 30

Group type: COMPARATOR
Intervention: NovoRapid
Number of subjects: 30
Study: 32357506

Group type: EXPERIMENTAL
Intervention: Actual motor competence
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Perceived motor competence
Number of subjects: 215
Study: 36398900

Group type: EXPERIMENTAL
Intervention: Morning intake of antihypertensive medications
Number of subjects: 21000

Group type: COMPARATOR
Intervention: Evening intake of antihypertensive medications
Number of subjects: 21000
Study: 33947979

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 58

Group type: COMPARATOR
Intervention: Topical loteprednol etabonate (0.1%) and topical olopatadine (0.1%)
Number of subjects: 58
Study: 33748058

Group type: EXPERIMENTAL
Intervention: Providing dispensers with sunscreens (SPF 50+) at construction sites and regular feedback on application through electronic monitoring.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Basic information on UV-exposure and skin protection provided to all groups.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Electronic monitoring of sunscreen consumption.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Skin check for actinic keratosis (AK) or NMSC at the end of the study.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Measurement of biomarkers from stratum corneum (SC) samples for internal UV-dose.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Personal UV-sensors worn by workers to assess external UV-dose.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Number of sunburn episodes recorded.
Number of subjects: 200
Study: 32410705

Group type: EXPERIMENTAL
Intervention: Neoadjuvant letrozole for 4 months
Number of subjects: 112
Study: 35072215

Group type: EXPERIMENTAL
Intervention: NMES with pulse width of 300 µs
Number of subjects: 46

Group type: COMPARATOR
Intervention: NMES with pulse width of 200 µs
Number of subjects: 46
Study: 32503662

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate (400 mg twice daily for seven days)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate
Number of subjects: 202
Study: 37001642

Group type: EXPERIMENTAL
Intervention: LCA subtypes with more severe depressive symptoms
Number of subjects: 629

Group type: COMPARATOR
Intervention: LCA mild subtype
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: All LCA subtypes
Number of subjects: 629
Study: 34886057

Group type: EXPERIMENTAL
Intervention: Philosophy for Children (P4C) intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 57
Study: 32660475

Group type: EXPERIMENTAL
Intervention: Housing intervention group (n = 99)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (n = 97)
Number of subjects: 196
Study: 36480230

Group type: EXPERIMENTAL
Intervention: New tracheal catheter fixation band
Number of subjects: 90

Group type: COMPARATOR
Intervention: 3M strong adhesive tape
Number of subjects: 90
Study: 33341066

Group type: EXPERIMENTAL
Intervention: Fluorescent concretization intervention education
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional education
Number of subjects: 126
Study: 33781107

Group type: EXPERIMENTAL
Intervention: Ketamine (0.44 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Active-placebo remifentanil
Number of subjects: 32
Study: 33208099

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (30 mg/kg loading dose over 10 min, then 10 mg/kg per h until 10 min before end of surgery)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (normal saline, equal volume to magnesium group, same regimen)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 33345840

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (fasting <90 mg/dL, 1 hour postprandial <120 mg/dL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard glycemic control (fasting <95 mg/dL, 1 hour postprandial <140 mg/dL)
Number of subjects: 60
Study: 35710213

Group type: EXPERIMENTAL
Intervention: Pilates program twice a week for 10 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (daily routines)
Number of subjects: 66
Study: 34516759

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 254

Group type: COMPARATOR
Intervention: Active Monitoring (AM)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Capecitabine and Active Monitoring (AM)
Number of subjects: 254
Study: 33474815

Group type: EXPERIMENTAL
Intervention: Oral synbiotics supplement (1 sachet daily for 12 weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (1 sachet daily for 12 weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Comparison between synbiotics and placebo at week 12
Number of subjects: 57
Study: 32856566

Group type: EXPERIMENTAL
Intervention: Activating Happiness© intervention
Number of subjects: 49
Study: 35973827

Group type: EXPERIMENTAL
Intervention: MitoHeal® 500 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MitoHeal® 1000 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 40
Study: 33437991

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST-IT)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 123
Study: 33316649

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 33022918

Group type: EXPERIMENTAL
Intervention: Combined exercise training (EXP; n = 10)
Number of subjects: 20
Study: 33550393

Group type: EXPERIMENTAL
Intervention: Cryo-Maze procedure
Number of subjects: 450
Study: 36364870

Group type: EXPERIMENTAL
Intervention: CALO mama Plus (intervention group)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 141
Study: 32013717

Group type: EXPERIMENTAL
Intervention: Abdominal drain placement (G1)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No abdominal drain placement (G2)
Number of subjects: 84
Study: 36203694

Group type: EXPERIMENTAL
Intervention: Active Brains digital intervention
Number of subjects: 360
Study: 34267550

Group type: EXPERIMENTAL
Intervention: galcanezumab 300 mg
Number of subjects: 106

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 106
Study: 33967202

Group type: EXPERIMENTAL
Intervention: Gemcitabine maintenance therapy after gemcitabine + platinum combination therapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gemcitabine + platinum combination therapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gemcitabine maintenance therapy
Number of subjects: 18
Study: 33040510

Group type: EXPERIMENTAL
Intervention: Endoscopic assisted lateral neck dissection
Number of subjects: 36

Group type: COMPARATOR
Intervention: Open lateral neck dissection
Number of subjects: 36
Study: 35785485

Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous (MIC) exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-load high-repetition (LLHR) resistance exercise
Number of subjects: 24
Study: 34092664

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (4, 12, 16 U/kg, maximum 100, 300, 400 U)
Number of subjects: 311
Study: 32915506

Group type: EXPERIMENTAL
Intervention: Nurse-led smartphone-based self-management programme (Care4Diabetes application)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Currently available nurse-led diabetes service
Number of subjects: 40
Study: 34216468

Group type: EXPERIMENTAL
Intervention: RT-PCR positive/seronegative
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: RT-PCR positive/seropositive
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seropositive
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Presence of SARS-CoV-2 antibodies
Number of subjects: 592
Study: 34121364

Group type: EXPERIMENTAL
Intervention: Relaxation condition
Number of subjects: 120

Group type: COMPARATOR
Intervention: Stress condition
Number of subjects: 120
Study: 32009491

Group type: EXPERIMENTAL
Intervention: Group STOR (shown the operating room)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group No STOR (not shown the operating room)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group STOR
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group No STOR
Number of subjects: 90
Study: 35449818

Group type: EXPERIMENTAL
Intervention: Copaiba oil (CPO) inhalation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Jojoba oil (control)
Number of subjects: 22
Study: 35414601

Group type: EXPERIMENTAL
Intervention: Successful reperfusion (eTICI ≥2b)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Unsuccessful reperfusion (eTICI <2b)
Number of subjects: 192
Study: 34481311

Group type: EXPERIMENTAL
Intervention: Video conferencing on an electronic device
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Video conferencing tool
Number of subjects: 112

Group type: COMPARATOR
Intervention: Face-to-face interaction
Number of subjects: 112
Study: 32160422

Group type: EXPERIMENTAL
Intervention: Olanzapine + 10 mg samidorphan tablets (OLZ/SAM)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Olanzapine + placebo tablets (olanzapine)
Number of subjects: 234
Study: 35702033

Group type: EXPERIMENTAL
Intervention: Active promotion through social media channels
Number of subjects: 48

Group type: COMPARATOR
Intervention: No active promotion
Number of subjects: 48
Study: 34600270

Group type: EXPERIMENTAL
Intervention: hHW (71 °C water)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: hPAA (400 ppm)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: hDBDMH600 (400 or 600 ppm hypobromous acid)
Number of subjects: 8

Group type: COMPARATOR
Intervention: hAW (ambient water)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Other interventions (3% lactic acid, 400 ppm peracetic acid, acidified 400 ppm peracetic acid)
Number of subjects: 8
Study: 32022434

Group type: EXPERIMENTAL
Intervention: Lovastatin treatment
Number of subjects: 0